Evidence map›Paper›PMID 38910486›Full record

ReviewMini reviews in medicinal chemistry2024

Advances in the Development of Non-Structural Protein 1 (NsP1) Inhibitors for the Treatment of Chikungunya Virus Infection.

Timoteo Delgado-Maldonado, Antonio Moreno-Herrera, Gildardo Rivera

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Timoteo Delgado-MaldonadoLaboratorio de Biotecnología Farmacéutica, Dept. of Biotechnologia Farmaceutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, 88710 Reynosa, México.
Antonio Moreno-HerreraLaboratorio de Biotecnología Farmacéutica, Dept. of Biotechnologia Farmaceutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, 88710 Reynosa, México.
Gildardo RiveraLaboratorio de Biotecnología Farmacéutica, Dept. of Biotechnologia Farmaceutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, 88710 Reynosa, México.ORCID 0000-0001-9842-4167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chikungunya is a re-emerging viral infection of worldwide concern, and new antiviral therapeutics are necessary to combat this disease. Inhibitors of the non-structural protein 1 (NsP1), which shows Methyltransferase (MTase) activity and plays a crucial in the Chikungunya virus (ChikV) replication, are exhibiting promising results. This review aimed to describe recent advances in the development of NsP1 inhibitors for the treatment of Chikungunya disease. High-throughput screening of novel ChikV NsP1 inhibitors has been widely performed for the identification of new molecule hits through fluorescence polarization, Western blotting, ELISA-based assay, and capillary electrophoresis assays. Additionally, cell-based assays confirmed that the inhibition of ChikV NsP1 abolishes viral replication. In summary, pyrimidine and pyrimidin-7(6H)-one derivatives, GTP and nucleoside analogs have been demonstrated to show inhibitory activity and are considered promising scaffolds that provide useful knowledge for the research and development of new NsP1 inhibitors as potential treatment of Chikungunya re-emerging disease.

Indexed as

Antiviral AgentsChikungunya FeverChikungunya virusViral Nonstructural ProteinsAnimalsDrug DevelopmentEnzyme InhibitorsHumansVirus ReplicationAntiviral AgentsEnzyme InhibitorsViral Nonstructural Proteinsaedes egypti.antiviralChikungunyaguanylyltransferaseinhibitorsmethyltransferase

Identifiers

PMID38910486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.